The global Acute Myeloid Leukemia (AML) therapeutics market is set to expand significantly, with projections indicating growth from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, according to a new report from Fact.MR. The market is expected to register a compound annual growth rate (CAGR) of 9.2% between 2026 and 2036, creating an absolute dollar opportunity of approximately USD 5.9 billion and expanding nearly 2.4 times its current value.
The growth trajectory reflects a fundamental shift in how AML is treated, moving away from traditional chemotherapy toward genomics-driven strategies and targeted therapies. As healthcare providers increasingly adopt molecular diagnostics and mutation-based treatment selection, patients are receiving more individualized care pathways designed to improve outcomes and reduce disease recurrence.
Targeted therapies are emerging as the leading drug class, expected to account for 36% of market share in 2026. These therapies, which target specific genetic abnormalities such as FLT3 and NPM1 mutations, offer enhanced efficacy and better tolerability compared to conventional treatments. The increasing availability of mutation-specific drugs is expanding options for patients with genetically defined AML subtypes.
Newly diagnosed AML represents the largest patient segment, holding 48% market share in 2026. Initial treatment regimens generate the highest therapy volumes as patients typically begin treatment immediately after diagnosis. Growing awareness and improved diagnostic capabilities are contributing to increased treatment initiation rates across both developed and emerging markets.
Hospitals remain the leading end-user, accounting for 55% of market demand, due to the intensive nature of AML treatment, which often requires inpatient management, blood transfusion support, and continuous monitoring. Hospital pharmacies also dominate the sales channel with a 49% share, reflecting the complexity of AML therapies and the need for specialized handling.
One of the strongest growth drivers is the increasing availability of therapies for relapsed and refractory AML patients. New oral targeted therapies, menin inhibitors, and mutation-specific treatments are expanding options for patients who previously had limited alternatives. Recent regulatory approvals continue to strengthen the treatment landscape.
According to Shambhu Nath Jha, Principal Consultant at Fact.MR: ‘Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. We see demand rising for oral targeted drugs and lower-intensity combinations. The future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability.’
Regional markets display strong growth potential, with South Asia and East Asia emerging as high-growth regions due to expanding cancer care infrastructure and increasing access to molecular diagnostics. Among key countries, India is projected to grow at an 11.8% CAGR, China at 10.9%, and the United States at 8.7%. North America continues to lead market revenues due to strong specialty pharmacy networks and high healthcare spending.
The competitive landscape features leading pharmaceutical companies such as AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, and Kura Oncology, all investing heavily in precision medicine, molecular diagnostics partnerships, and clinical trials. As mutation testing becomes more integrated into routine practice, treatment decisions will become increasingly personalized and data-driven, shaping the future of AML care.
For more details, the full report is available at Fact.MR’s AML Therapeutics Market Report. A sample report can be accessed at this link.
This news story relied on content distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is AML Therapeutics Market to Reach $10.1 Billion by 2036 Driven by Precision Oncology.